WO2017167233A1 - 一种奥贝胆酸的新结晶形式及其制备方法 - Google Patents

一种奥贝胆酸的新结晶形式及其制备方法 Download PDF

Info

Publication number
WO2017167233A1
WO2017167233A1 PCT/CN2017/078821 CN2017078821W WO2017167233A1 WO 2017167233 A1 WO2017167233 A1 WO 2017167233A1 CN 2017078821 W CN2017078821 W CN 2017078821W WO 2017167233 A1 WO2017167233 A1 WO 2017167233A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal
solvent
acid
oleic acid
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/078821
Other languages
English (en)
French (fr)
Inventor
张顺吉
王生
朱昶臻
田伟伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201780001557.9A priority Critical patent/CN107531744B/zh
Priority to US16/088,509 priority patent/US11161871B2/en
Publication of WO2017167233A1 publication Critical patent/WO2017167233A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to an E-type crystal of oleic acid and a process for the preparation thereof.
  • the compounds of formula (I) obtained according to the process of the invention are useful in the treatment of primary biliary cirrhosis and nonalcoholic fatty liver disease.
  • Obicholic acid is a farnesoid X receptor agonist that indirectly inhibits gene expression of cytochrome 7A1 (CYP7A1) by activating the farnesoid X receptor. Since CYP7A1 is the rate-limiting enzyme of bile acid biosynthesis, oleic acid can inhibit the synthesis of cholic acid and is used to treat primary biliary cirrhosis and nonalcoholic fatty liver disease.
  • CYP7A1 is the rate-limiting enzyme of bile acid biosynthesis
  • oleic acid can inhibit the synthesis of cholic acid and is used to treat primary biliary cirrhosis and nonalcoholic fatty liver disease.
  • Abecholic acid was successfully developed by Intercept Pharmaceuticals Inc. and was the first drug developed in the past 20 years to treat cholestatic liver disease. The study was used in patients who did not respond adequately or could not tolerate the old standard treatment drug ursodeoxycholic acid.
  • OCA oleic acid
  • the composite end point of clinical studies is that alkaline phosphatase is reduced by at least 15%, serum alkaline phosphatase activity is 1.67 times lower than the upper limit of normal, and bilirubin is in the normal range.
  • Alkaline phosphatase is used to indicate severe liver disease. The extent of a biomarker.
  • Patent No. CN201380043964.8 of Intercept Pharmaceutical Company of the United States discloses crystalline Form C of oleic acid.
  • the preparation method is a butyl acetate recrystallization method.
  • the obtained C-type crystal is a solvent compound. Due to the higher boiling point of butyl acetate (126 ° C), it is difficult to completely remove the solvent from the sample.
  • CN201380043964.8 uses a drying method at 80 ° C, but the oleic acid is highly unstable to heat, and drying at such a high temperature causes rapid degradation thereof to generate new impurities. However, if drying is carried out at a lower temperature, although the degradation is reduced, the residual solvent is difficult to remove. Therefore, there is still a need to find a method for crystallization of oleic acid which avoids the use of high boiling solvents.
  • the present invention provides oleic acid (as shown in formula (I)),
  • the compound of the formula (I) can be obtained as a crystalline product under an appropriate amount of solvent crystallization conditions, and the obtained crystalline product is subjected to X-ray diffraction and DSC detection, and it is found to be a crystal form having good stability, which we call E. Type crystal.
  • the DSC pattern of the E-type crystal in the present application shows a melting endothermic peak near 94.5 ° C, and the X-ray powder diffraction pattern is shown in Fig. 1.
  • the X-ray powder diffraction pattern expressed by 2 ⁇ angle using Cu-Ka radiation is shown.
  • the present invention also provides a method of preparing E-type crystals of oleic acid, the method comprising the steps of:
  • the solvent is selected from one or more of ethyl acetate, methyl acetate, propyl acetate, methyl formate, ethyl formate, and propyl formate, or at least one of them.
  • the crystal form of the obtained compound of the formula (I) was examined by differential scanning calorimetry (DSC) and X-ray diffraction pattern measurement, and the solvent residue of the obtained crystal was examined.
  • the E-form crystal of the compound of the formula (I) prepared according to the method of the present invention does not contain or contains only a low content of residual solvent, and meets the requirements of the national pharmacopoeia for the residual solvent of the pharmaceutical product, so that the crystal of the present invention can be compared It is used as a pharmaceutical active ingredient.
  • n-hexane and ethyl acetate are low-boiling solvents, they are easily removed during the drying process.
  • the crystal form of oleic acid E prepared by the method of the present invention only needs to be dried at 30 ° C for 1 to 2 hours to reach a constant weight. .
  • the crystal form of oleic acid C obtained according to the patent CN201380043964.8 butyl acetate crystallization method requires blast drying at 50 ° C for 4 hours to reach a constant weight, and butyl acetate still has a considerable residual amount.
  • the E-form crystal of the compound of the formula (I) prepared by the present invention has good stability under the conditions of illumination, high temperature and high humidity, and the crystal form stability is good under the conditions of grinding, pressure and heat. It can meet the medicinal requirements of production, transportation and storage, and the production process is stable and controllable, and can be adapted to industrial production.
  • the solvent residue obtained by crystallizing the E crystal form by using the method of the present invention and then converting to amorphous form is very low, and the first batch is not detected in the three batches of experimental results, the second batch of ethyl acetate is 150 ppm, and the tetrahydrofuran is 10 ppm; Three batches of ethyl acetate were 35 ppm and tetrahydrofuran was 10 ppm.
  • the present invention provides a method for purifying oleic acid comprising the step of converting crude oleic acid to form E.
  • said converting comprises the step of recrystallizing oleic acid using a solvent, wherein said solvent is selected from the group consisting of ethyl acetate, methyl acetate, propyl acetate, methyl formate, ethyl formate, and propyl formate.
  • a solvent is selected from the group consisting of ethyl acetate, methyl acetate, propyl acetate, methyl formate, ethyl formate, and propyl formate.
  • a solvent is selected from the group consisting of ethyl acetate, methyl acetate, propyl acetate, methyl formate, ethyl formate, and propyl formate.
  • the solvent is a mixed solvent of n-hexane/ethyl acetate.
  • the crude oleic acid used in the purification method can be produced by any method, and the purity thereof is not limited.
  • the present invention can further enhance the conversion of the crude product having a higher purity into the E crystal form by the step of converting the crude product having higher purity. Purity, such as a crude product having a purity greater than 98% or 99%.
  • the purification method further comprises the step of converting the crystalline form E of oobecholic acid to an amorphous form.
  • the method of transformation is well known in the art, for example, wherein the step of converting to an amorphous form can include the step of dissolving the crystalline form of oleic acid E in a base and precipitating it with an acid.
  • the base is an inorganic base, more preferably an aqueous NaOH solution.
  • the acid is a mineral acid, more preferably hydrochloric acid.
  • the crude oleic acid prepared by the conventional method has high purity, but still contains a relatively high content of impurities, which poses a safety hazard for administration, and the purification method of the present invention can make the arsenic having high purity itself.
  • the purity of the crude acid is further increased such that its total hetero-HPLC content does not exceed 0.5%, preferably does not exceed 0.4%, more preferably does not exceed 0.3%.
  • Figure 1 is an X-ray powder diffraction pattern of the compound I form crystal of the formula (I).
  • Figure 2 is a DSC chart of the Form I crystal of the compound of formula (I).
  • the crystals have characteristic peaks at about 3.07, 4.86, 5.21, 6.20, 7.15, 7.64, 8.18, 8.84, 9.86, 10.88, 12.31, 14.75, 15.28, 15.77 and 16.37.
  • the DSC spectrum is shown in Figure 2. There is a sharp melting endotherm peak of 94.5 ° C. This crystal form is defined as the E crystal form.
  • Example 1 The E-type crystalline product samples obtained in Example 1 were separately placed in an open position, and the stability of the samples under illumination (4500 Lux), heating (40 ° C, 60 ° C), and high humidity (RH 75%, RH 90%) conditions were examined.
  • the sampling time was 5 days and 10 days, and the purity of HPLC was shown in Table 1.
  • E-type crystalline solid was dissolved in sodium hydroxide solution (0.6 g of sodium hydroxide dissolved in 15 ml of purified water), and added dropwise to a hydrochloric acid solution (0.15 ml of hydrochloric acid dissolved in 15 ml of purified water), and stirred. The mixture was stirred for 1 hour, filtered, and the filter cake was washed with water four times and dried under reduced pressure to give 1.7 g of an amorphous solid (HPLC purity: 99.70%, in which the impurity A content was 0.22%).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)

Abstract

本发明涉及一种奥贝胆酸的新结晶形式及其制备方法。具体而言，本发明涉及奥贝胆酸的E型结晶及其制备方法。该晶型十分稳定，且溶剂残留低，适于工业化生产。

Description

一种奥贝胆酸的新结晶形式及其制备方法 技术领域
本发明涉及奥贝胆酸的E型结晶及其制备方法。根据本发明的方法制备获得的式(I)化合物可用于治疗原发性胆汁性肝硬化和非酒精性脂肪性肝病。
背景技术
奥贝胆酸属法尼醇X受体激动剂，通过活化法尼醇X受体，间接抑制细胞色素7A1(CYP7A1)的基因表达。由于CYP7A1是胆酸生物合成的限速酶，因此奥贝胆酸可以抑制胆酸合成，用于治疗原发性胆汁性肝硬化和非酒精性脂肪性肝病。
奥贝胆酸由美国Intercept制药公司研发成功，是二十年来首个研发用于治疗胆汁淤积性肝病的药物。研究用于那些对旧标准治疗药物熊去氧胆酸没有充分应答或不能耐受的患者。安慰剂对照的三期临床试验中，奥贝胆酸(OCA)提高了与肝移植风险降低相关的两个生物标志物的水平。临床研究的复合终点是碱性磷酸酶至少下降15％，血清碱性磷酸酶的活性低于正常上限的1.67倍，而胆红素在正常范围内，碱性磷酸酶是用来表示肝脏疾病严重程度的一种生物标记物。
Figure PCTCN2017078821-appb-000001
美国Intercept制药公司的专利CN201380043964.8公开了奥贝胆酸的结晶C型。其制备方法为乙酸丁酯重结晶法。得到的C型晶体为溶剂化合物。由于乙酸丁酯的沸点较高(126℃)，造成溶剂很难从样品中完全除去。CN201380043964.8中为了除去该溶剂，使用了80℃下干燥的方法，但是奥贝胆酸对热高度不稳定，在如此高的温度下干燥将导致其快速降解从而又产生新的杂质。而如果使用较低温度干燥，虽然降解减少，却又导致残留溶剂难以去除。因此，仍然需要研究找到避免使用高沸点溶剂的奥贝胆酸结晶方法。
发明内容
本发明提供了奥贝胆酸(如式(I)所示)，
Figure PCTCN2017078821-appb-000002
式(I)所示化合物在适量的溶剂结晶条件下可得到一结晶产物，对所得结晶产物进行了X-衍射及DSC检测，发现其是一种稳定性良好的晶型，我们称其为E型结晶。本申请中的E型结晶的DSC图谱显示在94.5℃附近有熔融吸热峰，X-射线粉末衍射图谱如图1所示，使用Cu-Ka辐射，以2θ角度表示的X-射线粉末衍射图谱，其中在约3.07，4.86，5.21，6.20，7.15，7.64，8.18，8.84，9.86，10.88，12.31，14.75，15.28，15.77和16.37有特征峰。作为本领域公知的常识，2θ角度的数值允许有一定的误差，例如±0.2都视为相同的2θ角度范围内。
本发明还提供了制备奥贝胆酸的E型结晶的方法，所述方法包括下述步骤：
1)将任意晶型或无定型的式(I)所示化合物加入适量的溶剂中，加热溶清后，冷却析晶；
2)过滤结晶并洗涤，干燥。
在步骤1)中，其中所述的溶剂选自乙酸乙酯、乙酸甲酯、乙酸丙酯、甲酸甲酯、甲酸乙酯、甲酸丙酯中的一种或几种，或者它们中的至少一种与正戊烷、正己烷、正庚烷或石油醚的混合溶剂；优选所述溶剂为正己烷/乙酸乙酯混合溶剂；在优选的实施方案中所述溶剂为正己烷/乙酸乙酯。通过差示扫描热分析(DSC)、X-衍射图谱测定，对得到的式(I)所示化合物结晶体进行了晶型研究，同时对所得结晶的溶剂残留进行了检测。
按照本发明的方法制备的式(I)所示化合物E型结晶不含有或仅含有较低含量的残留溶剂，符合国家药典规定的有关医药产品残留溶剂的限量要求，因而本发明的结晶可以较好地作为医药活性成分使用。
因为正己烷和乙酸乙酯等都是低沸点溶剂，很容易在干燥过程中除去，本申请方法制备的奥贝胆酸E晶型仅需在30℃鼓风干燥1～2小时即达到恒重。而按照专利CN201380043964.8乙酸丁酯结晶法得到的奥贝胆酸C晶型需要50℃鼓风干燥4小时才能达到恒重，并且乙酸丁酯仍有相当的残留量。
经研究表明，本发明制备的式(I)所示化合物的E型结晶在光照、高温、高湿的条件下稳定性良好，且在研磨、压力和受热等条件下，晶型稳定性良好，能够满足生产运输储存的药用要求，生产工艺稳定可控，能够适应于工业化生产。
申请人按照按CN201380043964.8中使用乙酸丁酯结晶后在80℃下干燥产物，发现所得固体颜色变化，这说明奥贝胆酸在80℃下不稳定，已经发生了降解；而使用50～60℃干燥，测得在C晶型中乙酸丁酯残留约6800ppm，将该晶型转化为无定型样品后，乙酸丁酯残留仍然达到约1800ppm。而使用本发明中的方法结晶得到E晶型再转为无定形的溶剂残留非常低，在三批实验结果中分别为第一批未检出，第二批乙酸乙酯150ppm，四氢呋喃10ppm；第三批乙酸乙酯35ppm，四氢呋喃10ppm。
另一方面，本发明提供了一种奥贝胆酸的纯化方法，包括将奥贝胆酸粗品转化为E晶型的步骤。优选地，其中所述转化包括使用溶剂将奥贝胆酸重结晶的步骤，其中所述溶剂选自乙酸乙酯、乙酸甲酯、乙酸丙酯、甲酸甲酯、甲酸乙酯、甲酸丙酯中的一种或几种，或者它们中的至少一种与正戊烷、正己烷、正庚烷或石油醚的混合溶剂；优选所述溶剂为正己烷/乙酸乙酯混合溶剂。所述纯化方法中使用的奥贝胆酸粗品可以是任意方法制备得到的，其纯度不受限制，特别地，本发明可以通过将纯度较高的粗品经过转化为E晶型的步骤进一步提高其纯度，例如纯度已经大于98％或99％的粗品。
进一步优选地，所述纯化方法还包括将奥贝胆酸的E晶型转化为无定型形式的步骤。所述的转化方法是本领域所熟知的，例如其中所述的转化为无定型形式的步骤可以包括将奥贝胆酸E晶型溶于碱中，使用酸使其析出的步骤。优选地，其中所述的碱为无机碱，更优选NaOH水溶液。优选地，所述的酸为无机酸，更优选盐酸。
通常常规方法制备得到的奥贝胆酸粗品虽然纯度较高，但是仍然含有较高含量的杂质，给药用造成了安全隐患，本发明的纯化方法能使得本身已经具有较高纯度的奥贝胆酸粗品的纯度进一步提高，使得其总杂HPLC含量不超过0.5％，优选不超过0.4％，更优选不超过0.3％。
附图说明
图1式(I)所示化合物I型结晶的X-射线粉末衍射图谱。
图2式(I)所示化合物I型结晶的DSC图谱。
具体实施方式
以下将结合实施例更详细地解释本发明，本发明的实施例仅用于说明本发明的技术方案，并非限定本发明的实质和范围。
实验所用的测试仪器
1、DSC谱
仪器型号：MettlerToledo DSC 1Staree System
吹扫气：氮气
升温速率：10.0℃/min
温度范围：40-350℃
2、X-射线衍射谱
仪器型号：Bruker D8Focus X-射线粉末衍射仪
射线：单色Cu-Kα射线(λ＝1.5406)
扫描方式：θ/2θ，扫描范围：2-40°
电压：40KV，电流：40mA
实施例1
取(1.0g)式(I)所示化合物(晶型C，按201380043964.8公开的方法制备)加入到10ml锥形瓶中，加入2ml正己烷和2ml乙酸乙酯，加热至60℃，溶清，自然降温至室温并搅拌20小时。固体抽滤后在30℃鼓风干燥2小时得到固体0.8g，收率为80％。该结晶样品的X-射线衍射谱图见图1。该结晶在约3.07，4.86，5.21，6.20，7.15，7.64，8.18，8.84，9.86，10.88，12.31，14.75，15.28，15.77和16.37处有特征峰。 DSC谱图见图2，有尖锐熔融吸热峰94.5℃，将此晶型定义为E晶型。
实施例2
取(1.0g)式(I)所示化合物(无定型)加入到10ml锥形瓶中，加入2ml乙酸乙酯，加热至65℃，溶清，自然降温至室温并搅拌20小时。固体抽滤后在40℃鼓风干燥1小时得到固体0.5g，收率50％。X-射线衍射谱图和DSC谱图对比后确定为E晶型。
实施例3
取(1.0g)式(I)所示化合物(无定型)加入到10ml锥形瓶中，加入3ml甲酸乙酯，加热至50℃，溶清，自然降温至室温并搅拌20小时。固体抽滤后在30℃真空干燥4小时得到固体0.6g，收率60％。X-射线衍射谱图和DSC谱图对比后确定为E晶型。
实施例4
取(1.0g)式(I)所示化合物(无定型)加入到10ml锥形瓶中，加入2ml乙酸乙酯和3ml正庚烷，加热至60℃，溶清，自然降温至室温并搅拌20小时。固体抽滤后在30℃真空干燥4小时得到固体0.85g，收率85％。X-射线衍射谱图和DSC谱图对比后确定为E晶型。
实施例5
将实施例1所得的E型结晶产物样品分别敞口平摊放置，考察在光照(4500Lux)，加热(40℃，60℃)，高湿(RH75％，RH90％)条件下样品的稳定性。考察取样时间为5天和10天，HPLC检测纯度见表1。
表1、式(I)所示化合物E晶型样品的稳定性比较
Figure PCTCN2017078821-appb-000003
稳定性考察结果表明式(I)所示化合物E型结晶样品在敞口放置的条件下，样品在高温条件下，样品略有降解，在光照/高湿条件下，稳定性则较好。
实施例6
将按实施例1方法制得的式(I)所示化合物E型结晶进行研磨、加热及压片处理，研究结果表明晶型稳定，详细的实验数据参见下表2。
表2.式(I)所示化合物E晶型特殊稳定性研究
Figure PCTCN2017078821-appb-000004
实施例7
将按实施例1方法制得的式(I)所示化合物E型结晶进行稳定性考察，放样条件为(30℃，RH65％)，考察取样时间为5天、10天和30天，研究结果表明E型结晶在放样条件下稳定，实验数据见表3。
表3.式(I)所示化合物E晶型稳定性研究
Figure PCTCN2017078821-appb-000005
实施例8
取6α-乙基-3α-(甲氧基甲基氧基)-7α-羟基-5β-胆烷-24-酸5.0g(可按WO2016045480中公开的方法制得)，加入80ml四氢呋喃、8ml盐酸，15ml纯化水，室温反应12小时。反应液减压浓缩，剩余物加入30ml乙酸乙酯和10ml纯化水，分液；有机相水洗、无水硫酸钠干燥、过滤、减压浓缩；剩余物加入10ml正己烷和5ml乙酸乙酯，加热至60℃搅拌30分钟，降温析晶，过滤，得奥贝胆酸粗品3.1g(HPLC纯度99.29％其中杂质A含量0.42％)；向粗品中加入6ml正己烷和6ml乙酸乙酯，加热至60℃，溶清，自然降温至室温并搅拌20小时。固体抽滤后在50℃鼓风干燥2小时得到E型结晶固体2.1g(HPLC纯度99.75％，其中杂质A含量0.21％)。
将E型结晶固体2.1g溶于氢氧化钠溶液(0.6g氢氧化钠溶于15ml纯化水)中，滴加至盐酸溶液(0.15ml盐酸溶于15ml纯化水)中，搅 拌1小时，过滤，滤饼水洗4次，减压干燥，得无定型固体1.7g(HPLC纯度99.70％，其中杂质A含量0.22％)。
结果表明使用正己烷/乙酸乙酯重结晶可有效提高样品的纯度，E型结晶转为无定型后纯度无明显变化。

Claims (13)

  1. 如式(I)所示化合物的E型结晶，其特征在于：使用Cu-Kα辐射，得到以2θ角度表示的X-射线粉末衍射图谱，所述结晶在约4.86，6.20，12.31和16.37处有特征峰
    Figure PCTCN2017078821-appb-100001
  2. 根据权利要求1所述的E型结晶，其特征在于：使用Cu-Ka辐射，得到以2θ角度表示的X-射线粉末衍射图谱，所述结晶在约3.07，4.86，5.21，6.20，7.15，7.64，8.18，8.84，9.86，10.88，12.31，14.75，15.28，15.77和16.37有特征峰。
  3. 根据权利要求1所述的E型结晶，其特征在于：使用Cu-Ka辐射，得到以2θ角度表示的X-射线粉末衍射图谱，所述结晶具有如图1所示的X-射线粉末衍射图谱，其中在约3.07，4.86，5.21，6.20，7.15，7.64，8.18，8.84，9.86，10.88，12.31，14.75，15.28，15.77和16.37有特征峰。
  4. 一种制备如权利要求1所述的式(I)所示化合物的E型结晶的方法，所述方法包括下述步骤：
    1)将任意晶型或无定型的式(I)所示化合物加入适量的溶剂中，加热溶清后，冷却析晶，其中所述的溶剂选自乙酸乙酯、乙酸甲酯、乙酸丙酯、甲酸甲酯、甲酸乙酯、甲酸丙酯中的一种或几种，或者它们中的至少一种与正戊烷、正己烷、正庚烷或石油醚的混合溶剂；优选所述溶剂为正己烷/乙酸乙酯混合溶剂；
    2)过滤，干燥。
  5. 一种药物组合物，含有权利要求1所述的E型结晶以及药学上可接受的载体。
  6. 权利要求1所述的E型结晶或权利要求5所述的组合物用于制备治疗原发性胆汁性肝硬化或非酒精性脂肪性肝病的药物中的用途。
  7. 一种奥贝胆酸的纯化方法，包括将奥贝胆酸粗品转化为如权利要求1所述的E晶型的步骤。
  8. 根据权利要求7所述的方法，其中所述转化包括使用溶剂将奥贝胆酸重结晶的步骤，其中所述溶剂选自乙酸乙酯、乙酸甲酯、乙酸丙酯、甲酸甲酯、甲酸乙酯、甲酸丙酯中的一种或几种，或者它们中的至少一种与正戊烷、正己烷、正庚烷或石油醚的混合溶剂；优选所述溶剂为正己烷/乙酸乙酯混合溶剂。
  9. 根据权利要求7或8所述的方法，还包括分离所得E晶型的步骤，优选所述分离方法为过滤。
  10. 根据权利要求9所述的方法，还包括将分离后得到的奥贝胆酸的E晶型转化为无定型形式或其它晶型形式的步骤。
  11. 根据权利要求10所述的方法，其中所述的转化为无定型形式的步骤包括将奥贝胆酸E晶型溶于碱中，使用酸使其析出的步骤。
  12. 根据权利要求11所述的方法，其中所述的碱为无机碱，优选NaOH水溶液。
  13. 根据权利要求11所述的方法，其中所述的酸为无机酸，优选盐酸。
PCT/CN2017/078821 2016-03-31 2017-03-30 一种奥贝胆酸的新结晶形式及其制备方法 Ceased WO2017167233A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201780001557.9A CN107531744B (zh) 2016-03-31 2017-03-30 一种奥贝胆酸的新结晶形式及其制备方法
US16/088,509 US11161871B2 (en) 2016-03-31 2017-03-30 Crystalline form of obeticholic acid and preparation method therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610201130.0 2016-03-31
CN201610201130 2016-03-31

Publications (1)

Publication Number Publication Date
WO2017167233A1 true WO2017167233A1 (zh) 2017-10-05

Family

ID=59962610

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/078821 Ceased WO2017167233A1 (zh) 2016-03-31 2017-03-30 一种奥贝胆酸的新结晶形式及其制备方法

Country Status (4)

Country Link
US (1) US11161871B2 (zh)
CN (1) CN107531744B (zh)
TW (1) TWI740922B (zh)
WO (1) WO2017167233A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019047989A3 (en) * 2017-09-05 2019-06-06 Zentiva, K.S. CRYSTALLINE FORMS OF (3α,5β,6α,7α)-6-ETHYL-3,7-DIHYDROXYCHOLAN-24-IC ACID
CN110156860A (zh) * 2018-02-11 2019-08-23 四川科伦药物研究院有限公司 一种高纯度奥贝胆酸的纯化方法
WO2019197962A1 (en) * 2018-04-09 2019-10-17 Biophore India Pharmaceuticals Pvt. Ltd Crystalline forms of (3α, 5β, 6α, 7α)-6-ethyl-3, 7-dihydroxycholan-24-oic acid (obeticholic acid) and processes thereof
CN112898369A (zh) * 2019-12-04 2021-06-04 博瑞生物医药（苏州）股份有限公司 用于制备奥贝胆酸的方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013192097A1 (en) * 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
CN105085597A (zh) * 2015-08-28 2015-11-25 成都百裕科技制药有限公司 一种无定型奥贝胆酸的制备方法
CN105175473A (zh) * 2015-08-19 2015-12-23 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN105777836A (zh) * 2015-04-09 2016-07-20 厦门蔚扬药业有限公司 奥贝胆酸的多晶型物及其制备方法
CN105801653A (zh) * 2014-12-30 2016-07-27 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CN105859814A (zh) * 2015-01-23 2016-08-17 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及其药物组合物
CN105985395A (zh) * 2015-02-13 2016-10-05 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及含有该化合物的药物组合物
WO2017008773A1 (en) * 2015-07-16 2017-01-19 Zentiva, K.S. Crystalline forms of obeticholic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
WO2016045480A1 (zh) 2014-09-28 2016-03-31 上海源力生物技术有限公司 一种奥贝胆酸的制备方法
CN105175476B (zh) * 2015-09-02 2016-12-28 施淑琴 一种从油茶饼粕中提取茶皂素的方法
CN105810653B (zh) 2016-05-03 2018-09-28 扬州国扬电子有限公司 一种设有可共用电极大臂的功率模块

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013192097A1 (en) * 2012-06-19 2013-12-27 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
CN105801653A (zh) * 2014-12-30 2016-07-27 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
CN105859814A (zh) * 2015-01-23 2016-08-17 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及其药物组合物
CN105985395A (zh) * 2015-02-13 2016-10-05 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及含有该化合物的药物组合物
CN105777836A (zh) * 2015-04-09 2016-07-20 厦门蔚扬药业有限公司 奥贝胆酸的多晶型物及其制备方法
WO2017008773A1 (en) * 2015-07-16 2017-01-19 Zentiva, K.S. Crystalline forms of obeticholic acid
CN105175473A (zh) * 2015-08-19 2015-12-23 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN105085597A (zh) * 2015-08-28 2015-11-25 成都百裕科技制药有限公司 一种无定型奥贝胆酸的制备方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019047989A3 (en) * 2017-09-05 2019-06-06 Zentiva, K.S. CRYSTALLINE FORMS OF (3α,5β,6α,7α)-6-ETHYL-3,7-DIHYDROXYCHOLAN-24-IC ACID
CN110156860A (zh) * 2018-02-11 2019-08-23 四川科伦药物研究院有限公司 一种高纯度奥贝胆酸的纯化方法
WO2019197962A1 (en) * 2018-04-09 2019-10-17 Biophore India Pharmaceuticals Pvt. Ltd Crystalline forms of (3α, 5β, 6α, 7α)-6-ethyl-3, 7-dihydroxycholan-24-oic acid (obeticholic acid) and processes thereof
CN112898369A (zh) * 2019-12-04 2021-06-04 博瑞生物医药（苏州）股份有限公司 用于制备奥贝胆酸的方法
CN112898369B (zh) * 2019-12-04 2024-09-17 博瑞生物医药（苏州）股份有限公司 用于制备奥贝胆酸的方法

Also Published As

Publication number Publication date
CN107531744A (zh) 2018-01-02
TW201736392A (zh) 2017-10-16
CN107531744B (zh) 2020-03-13
US11161871B2 (en) 2021-11-02
TWI740922B (zh) 2021-10-01
US20200299324A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
CN101679218B (zh) 晶体米诺环素碱及其制备方法
KR102522895B1 (ko) Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
WO2017167233A1 (zh) 一种奥贝胆酸的新结晶形式及其制备方法
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
JP2023062072A (ja) Ｒｏｒガンマの阻害剤
WO2013132511A1 (en) Novel polymorph of lurasidone hydrochloride
CN103298825A (zh) 具有所限定粒径的纯的非多晶型的结晶胆汁酸的优化合成
KR102657147B1 (ko) 빌라스틴의 결정형 및 그의 제조 방법
EP3565819B1 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
WO2019153644A1 (zh) 盐酸去亚甲基小檗碱晶型及其制备方法
CN102675395B (zh) 醋酸乌利司他的多晶型及其制备方法
WO2020049598A2 (en) Apalutamide polymorphs
US20210300917A1 (en) Solid State Forms of an Apoptosis-Inducing Agent and Processes Thereof
JP6670744B2 (ja) ヒオデオキシコール酸ナトリウム（ＮａＨＤＣ）の多形形態およびその調製方法
CN101925602B (zh) 基本上不含溶剂的阿巴卡韦的结晶形式
WO2020073984A1 (zh) 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
US12012421B2 (en) Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US12012420B2 (en) Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US20120253051A1 (en) Process for the preparation of ropinirole and salts thereof
WO2016050134A1 (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
WO2012046245A1 (en) Novel polymorph of lacosamide
CN101068827B (zh) 萨洒皂草配基的多晶型物
US12227506B2 (en) Crystalline polymorphs of 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and process for preparation thereof
WO2019011316A1 (zh) 一种btk激酶抑制剂的结晶形式及制备方法

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17773263

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17773263

Country of ref document: EP

Kind code of ref document: A1